1614
IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	STEER et al.	Group Art Unit:	1614
Serial No.:	10/532,039	Examiner:	Unassigned
Filed:	April 21, 2005	Docket No.:	110.01980101
371(c) Date:	September 22, 2005	Confirmation No.:	8552

Title: METHODS OF TREATING INJURIES OF THE NERVOUS SYSTEM ASSOCIATED WITH HEMORRHAGE

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

We are transmitting the following documents along with this Transmittal Sheet (which is submitted in triplicate):

X **Small entity status is entitled to be asserted in the above-identified application.**
X An itemized return postcard.
__ A Petition for Extension of Time for _ month(s) and a check in the amount of $__ for the required fee.
X A Supplemental Information Disclosure Statement (2 pgs); 1449 forms (4 pgs); and copies of 38 documents cited on the 1449 forms.
__ A request for continued examination (RCE) and a check in the amount of $ for the required filing fee.
__ A check in the amount of $__, representing ___.
__ A certified copy of a _ application, Serial No. _, filed _____, the right of priority of which is claimed under 35 U.S.C. §119.
X Other: Election Under 37 C.F.R. §3.71, Revocation, Power of Attorney and Certificate Under §3.73(b) (2 pgs., and copy of Assignment 3 pgs).
__ Amendment ___ No Additional fee is required. ___ The fee has been calculated as shown:

Fee Calculation for Claims Pending After Amendment					
	Pending Claims after Amendment (1)	Claims Paid for Earlier (2)	Number of Additional Claims (1-2)	Cost per Additional Claim	Additional Fees Required
Total Claims				x $25 =	
Independent Claims				x $100 =	
One or More New Multiple Dependent Claims Presented? If Yes, Add $180 Here →					
Total Additional Claim Fees Required					

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

CERTIFICATE UNDER 37 C.F.R. §1.8: The undersigned hereby certifies that this Transmittal Letter and the paper(s), as described hereinabove, are being deposited in the United States Postal Service, as first class mail, in a package addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 30 day of May, 2006.

MUETING, RAASCH & GEBHARDT, P.A.
Customer Number: 26813

By: Nancy A. Johnson
Name: Nancy A. Johnson
Reg. No.: 47,266
Direct Dial: 612-305-4723
Facsimile: 612-305-1228

PATENT
Docket No. 110.01980101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	STEER et al.	Group Art Unit:	1614
Serial No.:	10/532,039	Examiner:	Unassigned
Confirmation No.:	8552		
Filed:	April 21, 2005		
371(c) Date:	September 22, 2005		

For: METHODS OF TREATING INJURIES OF THE NERVOUS SYSTEM ASSOCIATED WITH HEMORRHAGE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of candor and good faith that is to be demonstrated before the United States Patent and Trademark Office (USPTO), enclosed are copies of documents which Applicants bring to the Examiner's attention as possibly being of interest in connection with the above-identified patent application. Per M.P.E.P. §609, the information cited in the present Supplemental Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 forms is respectfully requested. Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 forms, marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

It is believed that no fee is due, as this Supplemental Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 13-4895.

When the Examiner takes up the present application, consideration of these documents is respectfully requested. The Examiner is invited to contact Applicants' Representatives at the telephone number listed below if they can be of any assistance during prosecution of the present application.

CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 30 day of May, 2006.

Nancy A. Johnson

May 30, 2006
Date

NAJ/skd

Respectfully submitted
By
Mueting, Raasch & Gebhardt, P.A.
P.O. Box 581415
Minneapolis, MN 55458-1415
Telephone (612)305-1220
Facsimile (612)305-1228
Customer Number 26813

By:
Nancy A. Johnson
Reg. No. 47,266
Direct Dial (612)305-4723

INFORMATION DISCLOSURE STATEMENT	**Atty. Docket No.:** 110.01980101	**Serial No.:** 10/532,039
	Applicant(s): STEER et al.	**Confirmation No.:** 8552
	Application Filing Date: April 21, 2005 **371(c) Date:** September 22, 2005	**Group:** 1614
	Information Disclosure Statement mailed: May 30, 2006	

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		None					

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
		None						

OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

Examiner Initial	Copy Enclosed	Document Description
	✓	Abercrombie, "Estimation of Nuclear Population from Microtome Sections," *Anat. Rec.*, 1946;*94*:239-247.
	✓	Barker et al., "The Time Course of Loss of Dopaminergic Neurons and the Gliotic Reaction Surrounding Grafts of Embryonic Mesencephalon to the Striatum," *Exp. Neurol.*, 1996 Sep;*141*(1):79-93.
	✓	Björklund et al., "Intracerebral Grafting of Neuronal Cell Suspensions. II. Survival and Growth of Nigral Cell Suspensions Implanted in Different Brain Sites," *Acta. Physiol. Scand.*, 1983;*Supp. 522*:9-18.
	✓	Björklund et al., "Cell replacement therapies for central nervous system disorders," *Nat. Neurosci.*, 2000 Jun;*3*(6):537-544.
	✓	Branton et al., "Apoptosis in Primary Cultures of E14 Rat Ventral Mesencephala: Time Course of Dopaminergic Cell Death and Implications for Neural Transplantation," *Exp. Neurol.*, 1999 Nov;*160*(1):88-98.
	✓	Brundin et al., "Survival, growth and function of dopaminergic neurons grafted to the brain," *Prog. Brain Res.*, 1987;*71*:293-308.
	✓	Brundin et al., "Preparation and Intracerebral Grafting of Dissociated Fetal Brain Tissue in Rats," *Methods in Neurosciences, Vol. 7 Lesions and Transplation,* Conn, Ed., San Diego, CA, 1991;*7*:305-326.

EXAMINER	**Date Considered**

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

INFORMATION DISCLOSURE STATEMENT	**Atty. Docket No.:** 110.01980101	**Serial No.:** 10/532,039
	Applicant(s): STEER et al.	**Confirmation No.:** 8552
	Application Filing Date: April 21, 2005 **371(c) Date:** September 22, 2005	**Group:** 1614
	Information Disclosure Statement mailed:	May 30, 2006

Examiner Initial	Copy Enclosed	Document Description
	✓	Brundin et al., "Functional Effects of Mesencephalic Dopamine Neurons and Adrenal Chromaffin Cells Grafted to the Rodent Striatum," *Functional Neural Transplantation*, Dunnett et al., Eds., New York, NY, 1994;9-46.
	✓	Brundin et al., "Improving the Survival of Grafted Dopaminergic Neurons: A Review Over Current Approaches," *Cell Transplant.*, 2000;*9*:179-195.
	✓	Brundin et al., "Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease," *Brain*, 2000; *123*:1380-1390.
	✓	Brundin et al., "Transplanted dopaminergic neurons: More or Less?" *Nat. Med.*, 2001 May;*7*(5):512-513.
	✓	Clarkson et al., "GDNF reduces apoptosis in dopaminergic neurons *in vitro*," *NeuroReport*, 1995 Dec 29;*7*(1):145-149.
	✓	Clarkson et al., "GDNF improves survival and reduces apoptosis in human embryonic dopaminergic neurons in vitro," *Cell Tissue Res.*, 1997 Jul; *289*(1):207-210.
	✓	Duan et al., "Sequential Intrastriatal Grafting of Allogeneic Embryonic Dopamine-Rich Neuronal Tissue in Adult Rats: Will the Second Graft be Rejected?" *Neuroscience*, 1993;*57*(2):261-274.
	✓	Duan et al., "Temporal pattern of host responses against intrastriatal grafts of syngeneic, allogeneic or xenogeneic embryonic neuronal tissue in rats," *Exp. Brain Res.*, 1995; *104*:227-242.
	✓	Duan et al., "Quinolinic acid-induced inflammation in the striatum does not impair the survival of neural allografts in the rat," *Eur. J. Neurosci.*, 1998 Jul;*10*(7):2595-2606.
	✓	Duan et al., "Enhancement of Nigral Graft Survival in Rat Brain with the Systemic Administration of Synthetic Fibronectin Peptide V," *Neuroscience*, 2000; *100*(3):521-530.
	✓	Dunnett et al., "Cell therapy in Parkinson's disease - stop or go?" *Nat. Rev. Neurosci.*, 2001 May;*2*:365-369.

EXAMINER	**Date Considered**

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

INFORMATION DISCLOSURE STATEMENT	**Atty. Docket No.:** 110.01980101	**Serial No.:** 10/532,039
	Applicant(s): STEER et al.	**Confirmation No.:** 8552
	Application Filing Date: April 21, 2005 **371(c) Date:** September 22, 2005	**Group:** 1614
	Information Disclosure Statement mailed:	May 30, 2006

Examiner Initial	Copy Enclosed	Document Description
	✓	Emgard et al., "Patterns of Cell Death and Dopaminergic Neuron Survival in Intrastriatal Nigral Grants," *Exp. Neurol.*, 1999 Nov;*160*(1):279-288.
	✓	Falasca et al., "Protective Role of Tauroursodeoxycholate During Harvesting and Cold Storage of Human Liver," *Transplantation*, 2001 May 15;*71*(9):1268-1276.
	✓	Freed et al., "Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease," *N. Engl. J. Med.*, 2001 Mar 8;*344*(10):710-719.
	✓	Friman et al., "Ursodeoxycholic Acid Reduces Acute Rejection in Heart Allografted Rats," *Trans. Proc.*, 1992 Feb;*24*(1):344-345.
	✓	Grasbon-Frodl et al., "The Lazaroid U-83836E Improves the Survival of Rat Embryonic Mesencephalic Tissue Stored at 4°C and Subsequently Used for Cultures or Intracerebral Transplantation," *Brain Res. Bull.*, 1996;*39*(6):341-347.
	✓	Green et al., "Mitochondria and Apoptosis," *Science*, 1998 Aug 21; *281*(5380):1309-1312.
	✓	Kordower et al., "Functional Fetal Nigral Grafts in a Patient with Parkinson's Disease: Chemoanatomic, Ultrastructural, and Metabolic Studies," *J. Comp. Neurol.*, 1996 Jun 24;*370*(2):203-230.
	✓	Kroemer et al., "Mitochondrial control of cell death," *Nat. Med.*, 2000 May;*6*(5):513-519.
	✓	Lindvall, "Neural Transplantion," *Cell Transpl.*, 1995;*4*(4):393-400.
	✓	Mahalik et al., "Programmed Cell Death in Developing Grafts of Fetal Substantia Nigra," *Exp. Neurol.*, 1994 Sep;*129*(1):27-36.
	✓	Nakao et al., "Lazaroids improve the survival of grafted rat embryonic dopamine neurons," *Proc. Natl. Acad. Sci. USA*, 1994 Dec; *91*:12408-12412.
	✓	Piccini et al., "Dopamine release from nigral transplants visualized *in vivo* in a Parkinson's patient," *Nat. Neurosci.*, 1999 Dec;*2*(12):1137-1140.
	✓	Salvesen et al., "Caspases: Intracellular Signaling by Proteolysis," *Cell*, 1997 Nov 14; *91*:443-446.
	✓	Sauer et al., "Effects of cool storage on survival and function of intrastriatal ventral mesencephalic grafts," *Restor. Neurol. Neurosci.*, 1991;*2*:123-135.

EXAMINER	**Date Considered**

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

INFORMATION DISCLOSURE STATEMENT	**Atty. Docket No.:** 110.01980101	**Serial No.:** 10/532,039
	Applicant(s): STEER et al.	**Confirmation No.:** 8552
	Application Filing Date: April 21, 2005 **371(c) Date:** September 22, 2005	**Group:** 1614
	Information Disclosure Statement mailed:	May 30, 2006

Examiner Initial	Copy Enclosed	Document Description
	✓	Sauer et al., "Cryopreservation, survival and function of intrastriatal fetal mesencephalic grafts in a rat model of Parkinson's disease," *Exp. Brain Res.*; 1992; *90*:54-62.
	✓	Schierle et al., "Caspase inhibition reduces apoptosis and increases survival of nigral transplants," *Nat. Med.*, 1999 Jan;*5*(1):97-100.
	✓	Ungerstedt et al., "Quantitative Recording of Rotational Behavior in Rats after 6-Hydroxy-Dopamine Lesions of the Nigrostriatal Dopamine System," *Brain Res.*, 1970 Nov 11;*24*(1):485-493.
	✓	Zawada et al., "Growth Factors Rescue Embryonic Dopamine Neurons from Programmed Cell Death," *Exp. Neurol.*, 1996 Jul;*140*(1):60-67.
	✓	Zawada et al., "Growth factors improve immediate survival of embryonic dopamine neurons after transplantation into rats," *Brain Res.*, 1998;*786*:96-103.
	✓	Zuddas et al., "Specific Reinnervation of Lesioned Mouse Striatum by Grafted Mesencephalic Dopaminergic Neurons," *Eur. J. Neurosci.*, 1991 Jan 1;*3*(1):72-85.

EXAMINER	**Date Considered**

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**